Understanding how ZNF397 deficiency affects prostate cancer treatment resistance
Deciphering the Impact of ZNF397-deficiency in Promoting TET2-driven Epigenetic Rewiring, Lineage Plasticity, and Therapy Resistance in Prostate Cancer
This study is looking at how a missing ZNF397 gene affects prostate cancer cells, especially the tough kind that doesn't respond to standard treatments, to find new ways to help patients with advanced prostate cancer get better care.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-11235240 on NIH RePORTER |
What this research studies
This research investigates how a deficiency in the ZNF397 gene influences the behavior of prostate cancer cells, particularly their ability to change and resist treatments. By focusing on the aggressive form of prostate cancer known as metastatic castration-resistant prostate cancer (mCRPC), the study aims to uncover the mechanisms that allow these cancer cells to evade therapies targeting the androgen receptor. The researchers will explore the role of TET2, a gene that may serve as a new target for overcoming treatment resistance, potentially leading to more effective therapies for patients with advanced prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with metastatic castration-resistant prostate cancer who may be experiencing resistance to androgen receptor-targeted therapies.
Not a fit: Patients with early-stage prostate cancer or those not experiencing treatment resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that improve outcomes for patients with advanced prostate cancer.
How similar studies have performed: Other research has shown promising results in targeting similar mechanisms of treatment resistance in cancer, suggesting that this approach may yield valuable insights.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Mu, Ping — Yale University
- Study coordinator: Mu, Ping
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.